GlassScriptPhysician profile
Leah M Albrecht
NPI 1104366806
$2,017.58
in general payments reported to CMS, 2019-2025
23 companies · $358 in 2025
The $358 reported for 2025 was more than what 79% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $532 · 2022: $592 · 2023: $319 · 2024: $216 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.03 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.99 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $159.51 | 2022 | |
| Amgen INC. | $158.42 | 2021-2025 | Evenity, Prolia |
| Novo Nordisk INC | $117.86 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $75.35 | 2021 | |
| Pfizer INC. | $73.40 | 2023-2025 | |
| Lilly USA, LLC | $72.93 | 2021-2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $53.89 | 2021 | |
| Daiichi Sankyo INC. | $51.79 | 2022-2025 | Injectafer |
| Hologic Sales and Service, LLC | $50.30 | 2021-2025 | Thinprep 2000 Processor |
| Organon LLC | $49.80 | 2021-2022 | |
| Astellas Pharma US INC | $47.20 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $36.02 | 2021 | |
| Pharmacosmos Therapeutics INC. | $35.48 | 2024 | Monoferric |
| Sumitomo Pharma America, INC. | $27.88 | 2023 | Myfembree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $26.71 | 2024 | |
| Baxter Healthcare | $22.94 | 2022 | |
| Axsome Therapeutics, INC. | $22.80 | 2024 | Auvelity |
| Vertex Pharmaceuticals Incorporated | $22.03 | 2025 | |
| Merck Sharp & Dohme LLC | $21.07 | 2021 | |
| Currax Pharmaceuticals LLC | $16.64 | 2024 | Contrave |
| Eisai INC. | $14.32 | 2022 | |
| Exeltis, USA INC. | $14.25 | 2024 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Albrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.